Joel Jackson, an analyst from BMO Capital, maintained the Buy rating on Corteva. The associated price target is $86.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joel Jackson has given his Buy rating due to a combination of factors that highlight Corteva’s strong growth potential and financial resilience. He has raised the target price to $86, reflecting confidence in the company’s ability to achieve its projected EBITDA growth. The decision to roll forward the valuation multiple to 2026E EV/EBITDA underscores the expectation of continued positive performance, driven by robust growth in both seed and crop chemicals revenue.
Jackson’s analysis also points to the company’s strategic initiatives, such as the $1 billion buyback plan, which is expected to grow to $1.5 billion annually by 2026. This, coupled with anticipated margin expansion and the company’s ability to navigate industry challenges, positions Corteva as a leading player in the agricultural sector. The resilience of the seed segment is particularly noted as a mitigating factor against broader market challenges, supporting the overall positive outlook for Corteva’s stock.
In another report released on July 3, Citi also reiterated a Buy rating on the stock with a $0.00 price target.
CTVA’s price has also changed moderately for the past six months – from $57.030 to $76.580, which is a 34.28% increase.